Evidence map›Paper›PMID 38715256›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2024

Target organ damage in untreated hypertensive patients with primary aldosteronism.

Shi-Min Li, Jia-Yi Huang, Ching-Yan Zhu, Ming-Yen Ng, Qing-Shan Lin, Min Wu, Ming-Ya Liu, Run Wang, Gao-Zhen Cao, Cong Chen and 4 more

Abstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Target organ damage in untreated hypertensive patients with primary aldosteronism.Journal of clinical hypertension (Greenwich, Conn.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shi-Min LiDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Jia-Yi HuangDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.ORCID 0000-0003-1783-8195
Ching-Yan ZhuDivision of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Ming-Yen NgDivision of Radiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Qing-Shan LinDivision of Radiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Min WuDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Ming-Ya LiuDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Run WangDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Gao-Zhen CaoDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Cong ChenDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Mei-Zhen WuDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Qing-Wen RenDivision of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Hung-Fat TseDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.
Kai-Hang YiuDivision of Cardiology, Department of Medicine, The University of Hong Kong- Shenzhen Hospital, Shenzhen, China.ORCID 0000-0003-2145-3108

Funding

HKU-SZH Fund for Shenzhen Key Medical Discipline SZXK2020081Sanming Project of Medicine in Shenzen, China SZSM201911020
6 · The paper itself

Abstract

An increased risk of target organ damage (TOD) has been reported in patients with primary aldosteronism (PA). However, there is relatively little related research on the correlation between the degree of TOD and those with and without PA in newly diagnosed hypertensive patients. The aim of this study was to assess the association between PA and TOD among patients with newly diagnosed hypertension. Newly diagnosed hypertensive patients were consecutively recruited from January 2015 to June 2020 at the University of Hong Kong-Shenzhen Hospital. Patients were stratified into those with and without PA. Data for left ventricular mass index (LVMI), carotid intima-media thickness (CIMT) and plaque, and microalbuminuria were systematically collected. A total of 1044 patients with newly diagnosed hypertension were recruited, 57 (5.5%) of whom were diagnosed with PA. Patients with PA had lower blood pressure, serum lipids, body mass index, and plasma renin activity and a higher incidence of hypokalemia than those without PA. In contrast, the prevalence of left ventricular hypertrophy, increased CIMT, and microalbuminuria was higher in patients with PA than in those without PA. Multivariable regression analysis demonstrated that PA was independently associated with increased LVMI, CIMT and microalbuminuria. Among patients with newly diagnosed hypertension, those with PA had more severe TOD, including a higher LVMI, CIMT and microalbuminuria, than those without PA. These findings emphasize the need for screening TOD in newly diagnosed hypertension due to underlying PA.

Indexed as

AlbuminuriaCarotid Intima-Media ThicknessHyperaldosteronismHypertensionHypertrophy, Left VentricularAdultAgedBlood PressureFemaleHong KongHumansHypokalemiaMaleMiddle AgedPrevalenceRisk Factorsprimary aldosteronismtarget organ damageuntreated hypertension

Identifiers

PMID38715256
PMCPMC11232450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.